Reperfusion does not only salvage ischaemic myocardium but can also cause additional cell death which is called lethal reperfusion injury. The time of reperfusion is often accompanied by ventricular arrhythmias, i.e. reperfusion arrhythmias. While both conditions are seen as separate processes, recent research has shown that reperfusion arrhythmias are related to larger infarct size. The pathophysiology of fatal reperfusion injury revolves around intracellular calcium overload and reactive oxidative species inducing apoptosis by opening of the mitochondrial protein transition pore. The pathophysiological basis for reperfusion arrhythmias is the same intracellular calcium overload as that causing fatal reperfusion injury. Therefore both conditions should not be seen as separate entities but as one and the same process resulting in two different visible effects. Reperfusion arrhythmias could therefore be seen as a potential marker for fatal reperfusion injury.
Introduction
Reperfusion injury is the damage caused by inflammation, oxidative injury and electronic imbalance as a result of the return of blood flow to previously ischaemic tissue. Reperfusion of ischaemic myocardial tissue by thrombolysis or percutaneous coronary intervention (PCI) is essential effectively to reduce infarct size and increase clinical outcomes in patients presenting with acute myocardial infarction (AMI). However restoration of oxygenated blood flow also induces reperfusion injury. 1 Lethal reperfusion injury is defined as myocardial cell damage and/or death occurring as a result of the reperfusion of ischaemic but still viable cells. Clinical characteristics include an increase in chest pain and/or ST elevation, and a secondary plasma enzyme level rise after revascularisation. 2 Reperfusion can be accompanied by a high density of ventricular arrhythmias, typically consisting of ventricular premature beats with long coupling intervals and accelerated idioventricular rhythms typically starting within the first 20 minutes of reperfusion ( Figure 1 ). 3 In the thrombolytic era, without the support of angiographic imaging these arrhythmias were considered a beneficial sign, i.e. reopening of the infarct vessel by solution of the occluding clot. With the advent of PCI of the culprit coronary vessel it was found that ventricular reperfusion arrhythmias were associated with increased infarct size and decreased ventricular functioning despite optimal epicardial and microvascular flow and equal area at risk. [3] [4] [5] [6] [7] [8] [9] These findings suggest that the pathophysiological mechanisms of lethal reperfusion injury at the cellular level and reperfusion arrhythmias are intertwined. This review will focus on the pathophysiological mechanisms behind these occurrences and the clinical implications.
Myocellular death in ischaemic heart disease
Cell death in the setting of AMI and reperfusion can occur as a result of three different mechanisms. First because of ischaemia-induced necrosis after an extended time of ischaemia; furthermore, because of microvascular obstruction (MVO) occurring after epicardial reperfusion or third as a result of injury caused by reperfusion of ischaemic but viable myocardium, i.e. lethal reperfusion injury. 1, [10] [11] [12] [13] [14] [15] For the purpose of this review we will focus on lethal reperfusion injury but also give a short overview of the changes during ischaemia and the pathophysiology of MVO.
Ischaemic changes
In the first 10 seconds of ischaemia oxyhaemoglobin is exhausted and aerobic metabolism ceases (Figure 2) . 16, 17 After 15-20 seconds anaerobic glycolysis supervenes as the only source of high energy phosphate. At the same time the formation of nicotinamide adenine dinucleotide, reduced form 2 (NADH2) is favoured above nicotinamide adenine dinucleotide (NAD) formation and extracellular potassium concentrations start to rise, inducing arrhythmias. [16] [17] [18] [19] After 60-90 seconds the glycolysis starts to slow markedly because of the sarcosplasmic NADH2/ NAD ratio and low pH. At this time the majority of available adenosine triphosphate (ATP) is used for mitochondrial ATPase and myocardial contraction ceases. 15, [20] [21] [22] As ischaemia persists for 10-15 minutes, sodium/potassium (Na/K) ATPase activity causes a slight decrease in intracellular sodium while anaerobic glycolysis causes the formation of xanthine and hypoxanthine and pH lowering below 6 due to the intracellular rise in lactate and H+ 23 . After 20-40 minutes of ischaemia myocytes reach the last phase of reversible injury characterised by glycogen depletion, swelling of mitochondria, and further a rise in intracellular sodium and calcium. [16] [17] [18] [20] [21] [22] [23] [24] Figure 1. Three-dimensional graphic output from 12-lead digital ECG monitor (NEMON 180+, NorthEast Monitoring, Inc.), showing ST-segment level (mm) (y axis) for all 12 leads (z axis) with respect to time (x axis) in a study subject with anterior STsegment elevation myocardial infarction treated with primary percutaneous coronary intervantion presented as abrupt ST-segment resolution anterior myocardial wall leads V2-V6; V4 is the peak ST lead. The three upper panels show representative 12-lead ECGs with resolving ST-elevation, best seen in lead V4. The substantial data gap in the graphic at the time of ST-elevation resolution was caused by a sudden increase ('bursts') of ventricular arrhythmias from which ST-segment levels were excluded for graphic threedimensional continuous ST-segment recovery visualisation (from Majidi et al.) 3 Necrosis will extend from endocardium to epicardium in a wavefront manner finally causing transmural necrosis the longer ischaemia persists. 25, 26 Microvascular obstruction MVO is caused by two different processes, first by obstruction of the microvasculature by micro particles coming from the atherosclerotic plaque at the obstruction site that can become detached during PCI. 27 The second process involves cellular changes at the microvascular and myocellular level and is induced by the local ischaemia followed by reperfusion process (Figure 3(a) ). Experimental research in rabbits has shown that expansion of MVO occurs during the first 8 hours after reperfusion with almost a tripling between 2 and 120 minutes after reperfusion. [28] [29] [30] MVO due to cellular changes induced by reperfusion can cause luminal obstruction either from internal or by external compression of the capillaries. 14, 31, 32 The internal obstruction is related to processes such as oedema of the endothelium and leukocyte plugging. External compression is caused by swelling of myocytes, interstitial oedema and haemorrhage. The latter is caused by leakage of ischaemic injured capillary walls, while myocyte swelling is related to potassium efflux aggravated by reperfusion. Ischaemia followed by reperfusion also activates inflammation. Endothelial oedema is not the only result of inflammation that incites MVO. Damage associated molecular pattern molecules, produced as a result of necrosis, enter the circulation upon reperfusion and activate Toll-like receptors which in turn produce cytokines (interleukin (IL)-1, IL-6 and tumour necrosis factor alpha) causing IL-8 production and neutrophil accumulation ( Figure 3(b) ). 31, [33] [34] [35] [36] [37] At the same time accumulation of neutrophils is triggered by reactive oxygen species (ROS). 15, 32 IL-8 causes vasoconstriction by a decrease of nitric oxide, damage of β-adrenergic receptors and prostacyclin production. Vasoconstriction is further amplified by the production of platelet-activating factor by neutrophils and IL-8 that activates thromboxane A 2 . 15, 37, 38 This decrease in blood flow will aid the luminal obstruction of vessels by neutrophil plugging or thrombus formation by platelet-activating factor and complement activation.
Reperfusion at the myocellular level
Irreversible myocellular injury during reperfusion induces necrosis and apoptosis, the latter being an ATP dependent process that cannot occur during ischaemia. The pathophysiology behind reperfusion injury is roughly based on three mutually interfering mechanisms. These mechanisms include intracellular calcium overload, the production of ROS and neutrophil accumulation (Figure 4 (a)).
Intracellular calcium overload
Reperfusion of previous ischaemic tissue causes a wash out of extracellular electrolytes and leads to correction of intracellular acidosis with the help of the H+/Na+ exchanger, resulting in an increased intracellular sodium concentration. Due to the still present shortage of ATP, correction of the intracellular sodium concentration using Na+/K+ ATPase is deficient and is taken over by the reversed Na+/ Ca 2 + exchanger causing an intracellular calcium overload while enhancing potassium efflux. 1, 14, 39 Alongside the correction of acidosis, reperfusion enhances intracellular calcium overload by activation of the renin-angiotensin system that triggers angiotensin II release, which, in combination with the catecholamines released during ischaemia and reperfusion, induces further intracellular calcium release. 33, 40 Moreover, the reperfusion-initiated production of ROS increases calcium overload directly by damaging the sarcoplasmic reticulum. Finally, the interaction of ROS with free fatty acids leads to alpha-1 adrenergic receptor stimulation, which causes calcium overload by interaction with catecholamines. 1, 39, 41 
ROS production
Under normal circumstances ROS are only produced in small amounts, being immediately eradicated. However, large amounts are produced under stressful circumstances, such as after myocardial ischaemia. 15 Throughout ischaemia xanthine oxidase and hypoxanthine are formed, and on reperfusion oxygen starts to interact with xanthine oxidase and hypoxanthine producing ROS. 1, [42] [43] [44] Furthermore, ROS formation is also stimulated by intracellular Ca 2 + overload and catecholamines. 45 Moreover, the activation of the mitochondrial benzodiazepine receptor by ROS activates the inner membrane ion channel stimulating ROS formation, known as ROS-induced ROS formation. 46 Finally, neutrophils at the site of reperfusion are a major source of ROS, directly and through leukocyte-mediated activation of nicotinamide adenine dinucleotide phosphate, reduced form (NADPH) oxidase. 1 
Neutrophil accumulation
Neutrophils are present around the border of ischaemic tissue. Reperfusion enables neutrophils to infiltrate the area at risk. Neutrophil accumulation in non-reperfused myocardium is associated with slow infiltration into the area at risk in the first 12-24 hours of ischaemia and reaching peak concentrations after 2-4 days and mainly present around the border zone of the infarct. 47 However, neutrophil accumulation is accelerated and increased in reperfused myocardium although still occurring later than ROS formation and intracellular calcium overload, with higher concentrations found in the subendocardium compared to the subepicardium. 35 Figure 3. (a) Schematic representation of pathophysiological mechanisms that may contribute to reperfusion no reflow in the setting of primary angioplasty for acute myocardial infarction. The vasculature within the necrotic zone is subjected to additional injury after reperfusion. Microvascular spasm and plugging, intravascular thrombus, endothelial swelling and capillary compression by oedema within the adjacent myocardial tissue may lead to microvascular obstruction (MVO). Angioplasty-induced distal coronary embolisation of plaque and thrombus may compound the vascular obstruction. An inflammatory response may exacerbate this process, which leads to further myocardial ischaemia and cell death. Right: Interventional no reflow after non-infarct angioplasty is induced by distal coronary embolisation of plaque components. Mechanical obstruction of the microvasculature may be accompanied by an inflammatory vascular response that leads to vascular spasm. These mechanisms result in myocardial ischaemia and cell death. 27 (b) Schematic changes of MVO induced by reperfusion.
Neutrophils are activated by cytokines and ROS. The inflammatory response triggered by the activation and presence of neutrophils directly activates apoptosis, increasing final infarct size.
Opening mitochondrial permeability transition pore
It has been found that one of the most important key stones in lethal reperfusion injury is the opening of the mitochondrial permeability transition pore (mPTP), the latter being due to large amounts of ROS and intracellular calcium overload. 1, 39, 41, [43] [44] [45] [46] The mPTP is located in the inner membrane of mitochondria. The slight increase in intracellular calcium and ROS during ischaemia is not enough to open the pore because of the inhibitory effect acidosis has on the pore. After reperfusion, acidosis is resolved and concentrations of ROS and intracellular calcium increase causing opening of the mPTP. Indirectly ROS causes opening of the mPTP by activation of the inner membrane ion channel and by the induced collapse of mitochondrial membrane potential. 14, 48 Besides their stimulatory function in the production of ROS and intracellular calcium, catecholamines also promote mPTP opening.
The opening of the mPTP causes a decrease in pH, and increases intracellular calcium overload and ROS production (ROS-induced ROS production). mPTP opening causes the influx of other molecules inducing an increase in osmotic load, with mitochondrial swelling as result in addition to the increase in ROS and intracellular calcium. The swelling eventually causes the mitochondria to rupture and apoptotic proteins to be released. Cytochrome C released by mPTP opening activates the caspase cascade inducing apoptosis. 49 Furthermore, mPTP opening and intracellular calcium overload induce the uncoupling of oxidative phosphorylation. Uncoupling of oxidative phosphorylation triggers apoptosis by ATP hydrolyses leading to activation of degradative enzymes. 50 Finally, intracellular calcium overload can cause myocyte hypercontracture. Excessive hypercontracture can cause myocytes to tear away from tight intercellular junctions during hypercontracture, damaging the sarcolemmal of adjacent cells and can cause damage to cytoskeletal elements resulting in apoptosis. This manifests on histological examination as contraction band necrosis. 51 
Reperfusion arrhythmias
Clinically, reperfusion arrhythmias consist of ventricular arrhythmias, ranging from premature ventricular complexes to ventricular fibrillation but mainly consist of accelerated idioventricular rhythms. These arrhythmias have a configuration consistent with an origin from the ischaemic (reperfused) area. While first thought of as a beneficial sign, i.e. reopening of the infarct vessel, more recent studies have shown that reperfusion without arrhythmias resulted in smaller infarcts in spite of equal initial areas at risk. [3] [4] [5] [6] [7] [8] 
Pathophysiological mechanisms underlying reperfusion arrhythmias
The pathophysiological process behind reperfusion arrhythmias is not yet fully understood, but some relevant processes are known.
Delayed afterdepolarisations (DADs) are likely the most common electrophysiological cause of reperfusion arrhythmias. DADs are oscillations of the membrane potential, occurring after complete repolarisation of the preceding action potential. As is also the case in other pathologies, DADs after reperfusion are caused by intracellular calcium overload and are further amplified by calcium release by the sarcoplasmic reticulum upon the inflow of calcium into the cell. 44, [52] [53] [54] When the threshold is reached for the depolarising current, a spontaneous action potential will occur. This action potential can again induce an afterpotential resulting in self-sustaining rhythmic activity. Accelerated idioventricular rhythms have features consistent with the behaviour of DAD-related rhythms. 42, [55] [56] [57] In addition, intracellular calcium overload can cause reperfusion arrhythmias by uncoupling of oxidative phosphorylation, as described above. 41, 44, 58 Uncoupling of oxidative phosphorylation results in reduced concentrations of ATP, inducing shortening of action potential by the closure of K+ ATP channels. 48, 59 Correlation between fatal reperfusion injury and reperfusion arrhythmias
The pathophysiology of reperfusion arrhythmias has not yet been described in detail. The above described pathophysiology shows a process in which intracellular calcium overload is in the centre of triggering reperfusion arrhythmias. At the same time intracellular calcium overload is also a key component for inducing cell death in fatal reperfusion injury. It is therefore likely that reperfusion arrhythmias and fatal reperfusion injury are not two independent processes but two different outcomes of one and the same process, as is shown in Figure 2(a) . Consequently, reperfusion arrhythmias can be seen and used as a marker of lethal reperfusion injury.
This connection is supported by previous findings by our group. [3] [4] [5] [6] [7] [8] [9] We found, in several independent cohorts, the presence of a 'burst' of ventricular reperfusion arrhythmias (VA burst) to be related to clinically significant larger infarct size. This increase remained while correcting for other known factors of increased infarct size. In the presence of optimal epicardial and microvascular reperfusion the significant difference persisted. We tested whether VA burst was related to a larger area at risk but no relation was found.
Reperfusion arrhythmias as an electrobiomarker of reperfusion injury are rarely reported in clinical trials focusing on infarct size-reducing strategies. The above-mentioned pathophysiology and our clinical observations suggest that they could be an important early and unique marker for reperfusion injury. As such, reperfusion arrhythmias could become an early marker for risk stratification and for strategies to reduce reperfusion injury.
Treatment

Treatment of reperfusion injury
Prompt restoration of blood flow to the ischaemic tissue is essential for optimal salvage and to reduce mortality and morbidity in patients presenting with AMI. However, this does not prevent lethal reperfusion injury that can consist of up to 50% of final infarct size. 14 To prevent and reduce reperfusion injury, knowledge regarding its pathophysiology is essential. Various treatments have been tested and although different in site of action most of them have one common feature: although promising in preclinical trials, phase II and III clinical trials have rarely been shown to be successful. A number of reviews have recently been published in which the various recent trials and controversies are discussed. 10, 13, 14, [60] [61] [62] Figure 4(b) illustrates the different points of action of potential treatment options and how they fit into the pathophysiological mechanism of reperfusion injury. Above we described the pathophysiological relation between lethal reperfusion injury and reperfusion arrhythmias. However, most studies only focused on limiting the final infarct size without taking into account the all or no presence of reperfusion injury. The occurrence of ventricular arrhythmias were not reported in the majority of trials, although those that did showed a reduction in arrhythmias when the final infarct size was reduced. 33, 36, 42, 53, [63] [64] [65] [66] [67] [68] [69] Reduction of intracellular calcium overload has been an important focus in the prevention of reperfusion injury. Animal trials exist for fast Na+/H+ inhibitors, sodiumchannel inhibitors, Na+/Ca 2 + inhibitors, calcium antagonists, N-methyl-d-aspartate antagonists and angiotensin-converting enzyme inhibitors. 33, 40, 42, 52, 63, [70] [71] [72] [73] [74] Most have been carried out in rats, although also rabbits, dogs, guinea pig and swine models have been used. The drugs used reduced the incidence of ventricular premature beats, ventricular tachycardia, and/or ventricular fibrillation while at the same time reducing infarct size. In most trials, drugs were administered before the induction of ischaemia. If administered during ischaemia, treatments were less effective if effective at all for both arrhythmias and infarct size.
Another important factor in reperfusion injury is the production of ROS. Administration of ROS scavengers has been shown to reduce ventricular fibrillation and infarct size in rats and in some cases even ventricular tachycardia and mortality. 66, 67, 71, 75, 76 However, in all studies drug administration was carried out before ischaemia induction and the application of ROS scavengers in phase II and III trials did not reduce infarct size.
As discussed above, opening of the mPTP is a key component in reperfusion injury and is induced by intracellular calcium overload and ROS. Blockage of this pore by cyclosporine A, a strong mPTP inhibitor, reduced infarct size in animal studies. Also in a recent human pilot clinical trial it has been shown to reduce infarct size by 40% compared to control patients. 77 However, the larger CIRCUS trial found no significant reduction in infarct size. 78, 79 None of these trials reported the incidence of reperfusion arrhythmias; therefore the percentage of cases with reperfusion injury, possibly profiting from the intervention, was not known.
In addition beta-blockers have been used to reduce reperfusion injury, but results have been conflicting. This could have been due to different factors, which were extensively discussed in recent reviews. 80, 81 Both trials only focused on ventricular fibrillation and none on the incidence of reperfusion arrhythmias.
Pre, per and postconditioning
Pre, per and postconditioning comprise a particular niche in the prevention and treatment of reperfusion injury, because these interventions were not only beneficial in animal studies but also in human trials. 62, [82] [83] [84] [85] Preconditioning involves the administration of short periods of ischaemia or other interventions to the heart preceding a longer period of ischaemia. Indeed, the action of preconditioning seems to be supported by the observation of smaller infarct size in patients with angina in the 24 hours preceding AMI, and has been shown to reduce morbidity and mortality after coronary artery bypass graft surgery. [86] [87] [88] [89] Its 'anticipatory' aspect allows possible application in patients receiving cardiopulmonary bypass surgery 90 but clearly precludes AMI as an indication. The administration of short periods of ischaemia during or after ischaemia (peri and postconditioning) resulted in the same beneficial effects as preconditioning, with the advantage of being applicable in patients presenting with AMI. These interventions were applied mechanically by balloon re-inflation after balloon angioplasty, pharmacologically and by brief periods of ventricular pacing. 91 In addition, 'remote conditioning' has been studied: ischaemic stimuli applied to other parts of the human body, for example by brachialis compression by cuff inflation. [92] [93] [94] [95] Infarct size reduction reportedly was as high as 50% in animal studies. 39, [96] [97] [98] [99] However, most clinical trials have been neutral, currently preventing implementation into daily practice. 100 The disappointing translation from experimental studies to clinical trials could be caused be a number of reasons and are thoroughly discussed by Heusch. 62 Peri and postconditioning could be promising in humans, but conflicting results remain and the optimal protocol is still unknown. A different approach in translating the results of experimental studies in to clinical trials, as suggested by Heusch, 62 might be a way to reduce current inconsistencies.
Possible explanations for failure of treatment in patients
As discussed before, numerous potential treatments have failed to be effective in patients presenting with AMI while being effective in animal studies. Multiple explanations have been proposed, such as differences between animals and humans, duration of ischaemia and other variabilities in the clinical setting, i.e. pharmacological intervention only possible after the onset of ischaemia. Another important fact is that reperfusion injury cannot be explained as one simple mechanism but consists of redundant mechanisms induced by a sudden change from ischaemic to reperfused tissue. Therefore, prevention of reperfusion injury is unlikely to be obtained by manipulation of one single mechanism, and multiple pathways should be targeted simultaneously. Finally, for yet unknown reasons, reperfusion injury does not occur in every patient, leading to dilution of the treatment effect in clinical trials.
Conclusion
Reperfusion of ischaemic tissue is a double-edged sword by also causing additional damage to myocardial cells. The genesis of lethal reperfusion injury and reperfusion arrhythmias concentrates around intracellular calcium overload for both events. This conformity in their pathological basis led us to conclude that reperfusion arrhythmias and fatal reperfusion injury should be considered to have the same underlying pathophysiology. Reperfusion arrhythmias can therefore be seen as a marker of fatal reperfusion injury instead of an independent entity.
